To the Editor
It has come to our attention that the guidance about scan preparation for patients with type I diabetes in the European Association guideline for tumour imaging with FDG PET [1] contains a statement relating to management of individuals on 'insulin pumps' which may result in risk for some patients with type 1 diabetes undergoing imaging.
Individuals with type 1 diabetes treated with continuous sub-cutaneous insulin infusion (CSII) pumps are best managed by undertaking the scan early in the morning with the pump running on basal insulin rates alone to maintain euglycemia. In particular, such individuals should NOT discontinue the basal infusion as per the original text, as this creates a significant ketosis (± ketoacidosis) risk. Individuals in hospital using intravenous insulin delivery (usually as part of a combined insulin + dextrose + potassium infusion) are best managed by delaying their scan until such intravenous therapy is no longer required or (if urgent) by consultation with the local diabetes specialty team for individual advice.
Yours faithfully on behalf of all authors. Bernd Krause, Sally F Barrington and Iain Cranston.
